Costimulation pathway blockade in kidney transplant recipients with de-novo rheumatoid arthritis

Mohamed Sheta1, Samy Riad2, Udayakumar Deepak3, Naim Issa4, Mark Birkenbach5, Hassan N. Ibrahim2, and Aleksandra Kukla4

1South Carolina Nephrology/Hypertension, Orangeburg, SC, 2Division of Renal Diseases and Hypertension, 3Division of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, MN, 4Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, and 5Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA

Abstract. The best approach to treatment of de-novo rheumatoid arthritis in solid organ transplant recipients on typical immunosuppression is not well established. The use of biologics targeting specific cell types, cytokines, and immunological pathways has been gaining interest in the treatment of both, auto- and alloimmunity. We present a case of de-novo rheumatoid arthritis in a kidney transplant recipient 10 years post-transplant while receiving cyclosporine, mycophenolate mofetil, and also prednisone. Initial presentation included features of polymyalgia rheumatica and nephrotic range proteinuria. Kidney biopsy showed membranous nephropathy. The patient was initially treated with methotrexate, while mycophenolate mofetil was discontinued. Clinical symptoms improved, but creatinine significantly increased, which led to discontinuation of methotrexate and mycophenolate mofetil was restarted. The kidney function improved, but the patient experienced a flare of rheumatoid arthritis. Costimulatory blocker, abatacept, was initiated and cyclosporine was gradually tapered off. Graft function remained stable for a follow-up period of 7 years. Joint pain, weakness, and stiffness resolved. Follow-up plain film radiographs at 5 years post initial presentation showed no new joint erosions in hands or feet. Costimulatory blockers may broaden the therapeutic choices of transplant recipients with de-novo autoimmune diseases.

Case report

A 63-year-old white male, with a history of end-stage renal disease secondary to granulomatosis with polyangiitis (GPA), received a living donor kidney transplant in 1996. His past medical history included hypertension, coronary artery disease, gout, dyslipidemia, and obstructive sleep apnea. He was main-
Feet X-rays revealed erosions at the tarso-metatarsal joints. Based on clinical presentation, laboratory, and radiologic findings, the patient was diagnosed with RA with PMR features. Based on the clinical symptoms and laboratory findings, the patient met the 1987 American College of Rheumatology (ACR) classification criteria and the 2010 ACR classification criteria for the diagnosis of rheumatoid arthritis. The patient denied a family history of autoimmune diseases.

The patient underwent transplant kidney biopsy for evaluation of proteinuria. Light microscopy showed moderate interstitial fibrosis and tubular atrophy in a pattern which was attributed to cyclosporine exposure accompanied by mild scattered interstitial lymphoplasmacytic infiltrate and scattered tubulitis. Glomeruli demonstrated basement membrane spikes on silver Jones-stained sections, and direct immunofluorescence showed diffuse and global fine granular staining in peripheral capillary loops for IgG (1+) and C3. Electron microscopy showed subepithelial and intramembranous electron-dense deposits consistent with immune complexes, with rare subendothelial and scattered mesangial deposits also identified. In all, biopsy findings were consistent with membranous nephropathy (MN). There was no histological evidence of relapse of GPA.

The patient underwent thorough work-up for other autoimmune diseases and malignancy considering the strong association of MN with these conditions. Antinuclear antibody, antidualle-stranded deoxyribonucleic acid antibody, complement (C3, C4, and CH-50) levels, antineutrophil cytoplasmic antibodies (P-ANCA, C-ANCA), prostate specific antigen, hepatitis panel, colonoscopy, CT of the chest, abdomen, and pelvis were all unremarkable.
The patient was started on methotrexate, while mycophenolate mofetil was discontinued and prednisone dose was tapered down to 10 mg daily. He remained on cyclosporine. After 4 – 6 weeks of therapy, joint pains and stiffness improved, but creatinine increased to 3.6 mg/dL. Repeated kidney transplant biopsy results were consistent with previous findings. Given the lack of alternative explanations for acute worsening of kidney function, methotrexate was discontinued and mycophenolate mofetil was restarted at the dose of 750 mg twice a day. Kidney function improved. Approximately 3 weeks later, he presented with profound fatigue, synovitis over the proximal interphalangeal and metacarpophalangeal joints, and elevated inflammatory markers. Prednisone dose was increased to 40 mg daily and the patient was started on abatacept at the dose of 1,000 mg IV infusion every 4 weeks (weight: 120 kg), together with discontinuation of cyclosporine. 2 weeks after initiation of abatacept, his symptoms of myalgia, fatigue, and arthritis significantly improved. Prednisone was gradually tapered down to the current dose of 5 mg. Renal function stabilized (Figure 1). 7 years post initiation of abatacept, his creatinine is 1.5 mg/dL, and urine protein to creatinine ratio is 0.4 g/g of creatinine, while rheumatoid arthritis continues to be in remission (Table 1). The patient remained on abatacept, 1,000 mg IV infusion every 4 weeks, mycophenolate mofetil 750 mg daily and prednisone 5 mg daily. Plain film radiographs repeated 5 years post original diagnosis showed no new joint erosions in hands or feet.

**Discussion**

Treatment of RA in kidney transplant recipients poses a significant challenge. Patients are already exposed to immunosuppression and adding additional agents to control RA symptoms may lead to additive toxicity including increased risks of infection and malignancy. The patient described in our case report has not experienced any adverse effects related to immunosuppression. To our knowledge, only a single case report of de-novo RA in a kidney transplant recipient exists in a literature. Forslund et al. [1] reported de-novo seropositive erosive RA in a patient who was 7 years post deceased donor kidney transplantation for end-stage renal disease secondary to diabetes. Similarly to our case, the patient was receiving triple immunosuppression at the time of diagnosis, including cyclosporine, steroids, and azathioprine. Diagnosis was based on the clinical symptoms, elevated RF, CRP, and X-ray examination. The patient was switched from azathioprine to methotrexate, while cyclosporine and prednisone was continued. Contrary to our patient, he tolerated methotrexate well and had a good response to therapy with the resolution of clinical symptoms and normalization of inflammatory markers [1]. In nontransplant population, 30 – 40% of affected individuals may not adequately respond to methotrexate alone. For these patients, biologic disease-modifying antirheumatic drugs (DMARDs) are offered [2]. Our case report proposes that use of co-stimulatory pathway blockade in those challenging patients may be effective in controlling both auto- and alloimmunity. T-cells play a central role in adaptive immunity and therefore are involved in both allogeneic immune responses to transplanted organs and aberrant one, as seen in RA. Two signals are necessary for full T-lymphocyte activation: signal 1 is antigen-specific and is initiated by antigen-binding to the T-cell receptor complex; and signal 2, or costimulatory pathway involving interactions between CD28 molecule on T-lymphocyte surface and its ligands, CD80 and CD86 expressed on antigen-presenting cell (APC). CD86 seems to be more critical in initial T-cell activation, as it is constantly expressed on APC, with rapid up-regulation during initial T-cell-APC interaction. Up-regulation of CD80 requires more prolonged T-cell stimulation, and therefore may be more important in maintaining immune response [3].

Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is a transmembrane protein expressed in T-cells after activation that binds both CD80 and CD86 with higher affinity than CD28. By effectively competing with CD28 for ligand binding, CTLA-4 acts to suppress T-cell activation. This property has been exploited to develop immunosuppressive therapeutic agents. The first therapeutic inhibitor of the CD28 pathway com-
prised the extracellular domain of CTLA-4 fused to the Fc portion of immunoglobulin G (CTLA-4-Ig). This agent significantly prolonged graft survival in rodent transplantation models. Unfortunately, those results were not reproduced in non-human primates, likely due to significantly more potent ability of CTLA-4-Ig to inhibit CD 80 driven co-stimulation as compared to CD 86 [4]. When tested in patients with RA, CTLA-4-Ig use led to significant improvement in signs and symptoms of disease, as well as decreased progression of structural joint damage [5, 6, 7]. The fusion protein CTLA-4-Ig is commercially available as Orencia (abatacept). Subsequently, a modified version of CTLA-4-Ig (belatacept) was developed with much higher avidity to CD86 [3]. This agent is currently approved for maintenance immunosuppression in kidney transplant recipients, and it has shown to be as effective as traditionally used cyclosporine in prevention of acute rejection [8]. When tested in patients with RA in the pilot study, its effectiveness led to significant improvement in signs and symptoms of disease was comparable to abatacept [9].

The significant improvement in RA symptoms in our patient can be attributed to the use of abatacept. Its role in maintenance post-transplant immunosuppression, however, is less certain. Low immunologic-risk transplant recipients may be adequately immunosuppressed with mycophenolate mofetil and prednisone alone following cyclosporine withdrawal [10]. Therefore, it seemed feasible to discontinue cyclosporine with an introduction of abatacept in this case. Belatacept could have been considered in our patient, but was not approved in kidney transplantation at his initial presentation.

Conclusions

Abatacept may broaden the therapeutic choices of transplant recipients with de-novo RA and possibly others. This case illustrates its potential utility.

Conflict of interest

Authors declare no conflicts of interest and no sources of support.

References

[1] Forslund T, Ahonen J, Elomaa E, Parviainen T, Matinlauri I. De novo seropositive rheumatoid arthritis during immunosuppressive treatment after kidney transplantation. Clin Nephrol. 2005; 64: 231-235. CrossRef PubMed
[2] Yuzici Y. Treatment of rheumatoid arthritis: we are getting there. Lancet. 2009; 374: 178-180. CrossRef PubMed
[3] Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med. 2007; 58: 347-358. CrossRef PubMed
[4] Levisetti MG, Padrid PA, Szołt GM, Mitalla N, Meehan SM, Wardrip CL, Gray GS, Bruce DS, Thisuttlewaite JR Jr; Bluestone JA. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol. 1997; 159: 5187-5191. CrossRef PubMed
[5] Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, Teng J, Kremer JM. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis. 2008; 67: 1084-1089. CrossRef PubMed
[6] Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougdas M. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008; 67: 547-554. CrossRef PubMed
[7] Schiff M, Pritchard C, Hufstatter JE, Rodriguez-Valverde Y, Durez P, Zhou X, Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009; 68: 1708-1714. CrossRef PubMed
[8] Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blanche G, Lang P, Griñyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Nataranjan K, Charpentier B; Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005; 353: 770-781. CrossRef PubMed
[9] Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002; 46: 1470-1479. CrossRef PubMed
[10] Abramowicz D, Del Carmen Rial M, Vitko S, del Castillo D, Manas D, Luo M, Gafner N, Wijngaard P, Cyclosporine Withdrawal Study Group. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol. 2005; 16: 2234-2240. CrossRef PubMed